anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, oncology. SUBSTANCE: it is suggested as dependent upon character and severity of a disease to inject parenterally a combined AFP-containing preparation at 0.07-0.15 mg, polyenic antibiotic, predominantly amphotherycin B or nistatine at 4.2-7.0 mg and a filler, once daily at 3-d-long interval, at therapy course consisted of 10 infusion-drop injections. Combined preparation of antitumor action contains the following components, mg: AFP 0.07-0.15, polyenic antibiotic 4.2-7.0, filler 3.5-5.0. As a filler it is predominantly used polysaccharide of rheopolyglukin, polyglukin or sugar group, for example, glucose. EFFECT: decreased doses of injected medicinal preparations and therapy cost, increased efficiency of antitumor action, decreased quantity of components, simplified production and prolonged storage period. 4 cl
PURPOSE:To simply produce metal colloid having stability over a long period of time and capable of being well absorbed in the human body when used in foods, pharmaceuticals, cosmetics, etc., by mixing at least one of salts, hydroxides or oxides of metals with sugar phosphate in an aq. medium. CONSTITUTION:At least one of salts, hydroxides or oxides of metals, preferably Fe, Zn, Ti, Al, Sn, Cu, Ni, Si, Mg, Ba, Sr, V, Mn, Mo and Ag is mixed with sugar phosphate (e.g. glucose 1-phosphate, mannose 6-phosphate or p- glycerophosphoric acid) or a salt thereof in an aq. medium to obtain desired metal colloid. The pH of a soln. prepd. by the mixing is preferably 4-10.
Twelve eligible renal transplant recipients with PTDM and twelve age, gender, BMI and renal function-matched non-diabetic renal transplant recipients will be randomized to continuous unblinded intravenous infusion of GLP-1 with an infusion rate of 0.8 pmol/kg/min or isotonic saline (placebo) on two experimental days performed 2-4 weeks apart. The GLP-1 infusion will consist of 42.5 nmol/mL GLP-1 (7-36) amide, 12.5 mL 5% human albumin and isotonic saline added to a total volume of 50 mL. After 60 min, a 2 hour hyperglycemic clamp will be initiated, where plasma glucose will be elevated by 5 mmol/L from each individual fasting plasma glucose in both groups. This will be done to measure concentrations of glucagon and insulin in hyperglycemic conditions.
This study determined whether consumption of a highly palatable liquid is a reliable measure of inflammatory pain and antinociception in male and female rats. After a 10-day acquisition period, the impact of intraplantar oil vs. complete Freund adjuvant (CFA) on consumption of vanilla-flavored Ensure was assessed, with a sipper tube height 12 or 19 cm above the floor. CFA significantly decreased Ensure consumption, which completely recovered within 4-7 days to levels in oil-treated controls; neither sex nor sipper tube height significantly influenced Ensure consumption. CFA also significantly suppressed Ensure consumption in rats not exposed to the 10-day acquisition period, but only in males. To test the predictive validity of Ensure consumption as a measure of pain, separate rats were pretreated with a vehicle, an opioid, a nonsteroidal anti-inflammatory drug, or a cannabinoid the day after CFA treatment. Morphine and ibuprofen significantly attenuated CFA-suppressed drinking in at least one sex, and tetrahydrocannabinol did not. Neither ibuprofen nor tetrahydrocannabinol significantly altered drinking in oil-injected, 'pain-free' controls, but morphine increased drinking. These results demonstrate that CFA decreases consumption of a highly palatable liquid regardless of previous exposure (training) to the consumption procedure, but only in males. Although standard analgesics attenuate CFA-suppressed drinking, nonspecific hyperphagic effects can confound the interpretation of results. Thus, consumption of a highly palatable liquid is not an optimal measure for candidate analgesic screening.
Because most of the recent "Partner Notification" methods are a kind of afterwards remedial measures and will fail to find some of the infected MSM, researchers propose a preventive measures before they meet together. For MSM who are seeking potential sexual partners through Internet, researchers will encourage them to query health status before they decide to meet each other in order to promote their healthy self-responsibility consciousnes including avoiding HIV and other STDs infection, which will form a real ,digital MSM cohort. Researchers designed a pragmatic stepped wedge cluster randomized controlled trial to evaluate the effect of an intervention paradigm that provides HIV, syphilis, hepatitis B, and hepatitis C status partner notification based on the existing HIV and STDs control methods through an mHealth application (app), to reduce HIV and STDs incidences among MSM in China. More than 6000 MSM of 16 districts in Beijing, China will be grouped into four arms, each arm will cover four indepednent districts of Beijing randomly. The four arms will be randomized to sequentially initiate partner notification intervention through the app at 6-month intervals. All participants will be provided informed consent in the app after a full explanation of the protocol design. Researchers expect that the HIV incidence will be significantly lower and the secondary outcomes will also be better after partner notification intervention. The feasible and affordable public health management paradigm will have implications for HIV and STDs prevention and control among MSM and other key populations.
1. Micronised particles of colistin sulphomethate sodium wherein at least 90% by volume of the micronised particles have a diameter of less than 10 micrometers for use in the treatment of a pulmonary infection by powder inhalation, wherein the colistin sulphomethate sodium is not separated into component form. 2. A composition comprising micronised particles as they are determined in Claim 1 mixed with a carrier comprising lactose. 3. A composition as claimed in Claim 2 in the absence of free liquid. 4. A pharmaceutical dosage form suitable for use with a dry powder inhaler comprising micronised colistin sulphomethate sodium wherein at least 90% by volume of the particles have a diameter less than 10 micrometers and a container, said dosage having a content of below 10 wt % water. 5. A pharmaceutical dosage form suitable for use with a dry powder inhaler comprising a composition of Claim 3 and a container, said dosage having a content of below 10 wt % water. 6. A pharmaceutical dosage form of Claim 4 or 5, which additionally comprises a broncholytic drug. 7. A pharmaceutical dosage form of Claim 4 or 5, wherein the container is a hard gelatin capsule. 8. A capsule containing micronised colistin sulphomethate sodium wherein at least 90% by volume of the micronised particles have a diameter of less than 10 micrometers. 9. A capsule as claimed in Claim 8 containing from 10 to 200 micrograms of micronised colistin sulphomethate sodium.
Chronic pain management is complex. 27.2 to 43.5 % of general population suffers from it. Opoid crisis has shown the limit of the WHO 3 step analgesic ladder. Multidisciplinary pain management programs, shared decision making and non pharmacological interventions targeting subject's empowerment are needed. Among these non pharmacological interventions, patients are increasingly turning to traditional and complementary medicines. Evidence about their safety and efficacy is hard to build. Thus our study aims to assess the feasibility of a systematic proposal for non pharmacological interventions targeting the subject's empowerment.
A Ca 2+   dependent monoclonal antibody that specifically binds to a specific twelve peptide sequence (E D Q V D P R L I D G K) in the activation region of the Protein C. The antibody does not bind to Activated Protein C and can be used to inhibit activation of Protein C by thrombin-thrombomodulin. The antibody can be isolated from cell culture or ascites fluid in large quantities by affinity chromatography with mild conditions using the peptide bound to an immobilized substrate. The antibody has a number of specific uses in isolation and characterization of Protein C and as a model for the design of Ca 2+   dependent antibodies for the isolation of other proteins, as a diagnostic, and as a therapeutic to prevent activation of Protein C. The Protein C can be naturally produced or produced by expression of the recombinant gene. Advantages of the antibody in purification of Protein C include the specificity for Protein C and not Activated Protein C, and the unique Ca 2+  -peptide binding specificity which allows the binding site to be protected when it is being immobilized on the chromatographic support. In vivo, the antibody has been demonstrated to inhibit tumor growth. The antibody can also be used to promote clotting in patients having high levels of Factor VIII inhibitors.
BMIs are associated with reductions in alcohol consumption and related problems, but effect sizes are generally small. One BMI trial indicated that behavioral economic variables such as low levels of proportionate substance-free reinforcement and inelastic demand for alcohol predicted poor intervention response, and that participants who successfully reduced their drinking increased their participation in academic and other substance-free activities. A subsequent NIAAA R21 developed a substance-free activity session (SFAS) supplement to traditional alcohol BMIs that attempted to increase engagement in constructive alternatives to drinking by enhancing the salience of delayed rewards (academic and career success) and the patterns of behavior (academic engagement) leading to these outcomes. This study indicated that a two session (alcohol BMI + SFAS) preventive intervention resulted in significantly greater reductions in alcohol problems relative to a two session (alcohol BMI + Relaxation) active control condition. The BMI+ SFAS was also associated with significantly greater reductions in heavy drinking for participants with lower levels of substance-free reinforcement at baseline. This was the first controlled study to demonstrate that a supplement to traditional BMIs can improve outcomes. The current study will extend these promising pilot results by (a) increasing the efficacy of the behavioral economic SFAS by including booster contact, (b) increasing power and generalizability by recruiting 425 students from two universities and including a no-treatment control group, (c) measuring drinking, as well as behavioral economic mechanisms as mediators and moderators of intervention outcomes (delay discounting, alcohol reinforcing efficacy, substance-free reinforcement) at 5 time points over a sixteen month period, and (d) evaluating the economic costs and benefits associated with the SFAS. The goals of the SFAS - increasing student engagement in academic, campus, and career-related activities- are consistent with the priorities of most colleges.
The control group will receive Treatment-as usual (TAU), defined as the standard care provided to individuals struggling with self-harm (SH) as detailed within the 'Managing SH in primary care' NICE guidelines. These include: an initial comprehensive psychosocial assessment of skills and risks; co-production of a care and risk management care plan, which should include harm reduction plans, the need for between 3 and 12 sessions of psychological intervention as well as treatment for associated mental health conditions. Primary care practices in the control arm will be asked to provide information on what constitutes TAU within their organisation. This trial may enhance TAU as researchers will provide details of NICE guidance to GP practices that may not currently be following these guidelines. We will collect data regarding the acceptability of TAU for SH offered by GPs within both treatment arms.
PURPOSE:To obtain the titled cosmetic, containing a higher fatty acid salt, colloidal hydrous silicate and further a compound selected from aldonic acid and aldonolactone and having excellent usability and emulsion stability. CONSTITUTION:The titled cosmetic containing a higher fatty acid salt (preferably Na, K and triethanolamine salt) expressed by formula I (R is 11-21C straight-chain or branched alkyl or alkenyl; M is alkaline metal, ammonium, alkanolamine, etc.), a colloidal hydrous silicate (e.g. montmorillonite) and further one or two or more selected from aldonic acid (preferably gluconic acid) and aldonolactone (preferably glucono-delta-lactone) expressed by formula Il (n is >=3). This cosmetic is capable of exhibiting the same weak acidity as that of skin surface and simultaneously has excellent emulsion stability. The aldonic acid, etc., are preferably dissolved in water and added before previous emulsification from aspects of preventing smell from changing.
In the main study (FE200486 CS02; NCT00819247) loading doses of degarelix 80 mg were given on Days 0 and 3. Maintenance doses of 40 mg were given on days 28, 56, 84, 112 and 140. In the extension study (FE200486 CS02A) the same maintenance dose of degarelix was given once every 4 weeks.
Telehealth intervention involving the HEARTS technical package and the use of Smartwatch Mi Band 7® activity monitor. The HEARTS technical package presents the 5As brief intervention (Ask, Advise, Assess, Assist, Arrange) to promote physical activity participation. Participants will receive a physical activity monitor (as instructed in the HEARTS technical package) and will be monitored by telephone call, once a week, in order to reinforce successes and identify solutions to difficulties (as instructed in the HEARTS technical package) to practice physical activity. These individuals will undertake a 12-week intervention program. In the first week, individuals will perform the first four steps of the 5As brief intervention in person, where they will be instructed on how to use the physical activity monitor, they will receive a diary of regular physical activity practice, will be guided on how to fill it out, and will schedule the best times to receive the weekly telephone call.
BACKGROUND: The emergence of SARS-CoV-2 variants led to subsequent waves of COVID-19 worldwide. In many countries, the second wave of COVID-19 was marked by record deaths, raising the concern that variants associated with that wave might be more deadly. Our aim was to compare outcomes of critically-ill patients of the first two waves of COVID-19.
METHODS: This retrospective cohort included critically-ill patients admitted between March-June 2020 and April-July 2021 in the largest academic hospital in Brazil, which has free-access universal health care system. We compared admission characteristics and hospital outcomes. The main outcome was 60-day survival and we built multivariable Cox model based on a conceptual causal diagram in the format of directed acyclic graph (DAG).
RESULTS: We included 1583 patients (1315 in the first and 268 in the second wave). Patients in the second wave were younger, had lower severity scores, used prone and non-invasive ventilatory support more often, and fewer patients required mechanical ventilation (70% vs 80%, p<0.001), vasopressors (60 vs 74%, p<0.001), and dialysis (22% vs 37%, p<0.001). Survival was higher in the second wave (HR 0.61, 95%CI 0.50-0.76). In the multivariable model, admission during the second wave, adjusted for age, SAPS3 and vaccination, was not associated with survival (aHR 0.85, 95%CI 0.65-1.12).
CONCLUSIONS: In this cohort study, patients with COVID-19 admitted to the ICU in the second wave were younger and had better prognostic scores. Adjusted survival was similar in the two waves, contrasting with record number of hospitalizations, daily deaths and health system collapse seen across the country in the second wave. Our findings suggest that the combination of the burden of severe cases and factors such as resource allocation and health disparities may have had an impact in the excess mortality found in many countries in the second wave.
PROBLEM TO BE SOLVED: To obtain a synthetic resin material which has excellent efficacy in respect of therapeutic function, impurity-scavenging function, growth- promoting function and the like, and can be widely applied to a useful life of human being by using a synthetic resin contg. a nephrite powder. SOLUTION: This synthetic resin material comprises 5 to 15wt.% nephrite powder. More specifically, the synthetic resin material comprises: a molding of a thermoplastic resin, a thermosetting, general-purpose resin, or an ABS resin; and 5 to 15wt.% nephrite powder. The particle size of the nephrite powder is pref. 100 to 350 mesh.
Losartan, administered for 12 days, did not affect the pharmacokinetics or pharmacodynamics of a single dose of warfarin. Losartan did not affect the pharmacokinetics of oral or intravenous digoxin. There is no pharmacokinetic interaction between losartan and hydrochlorothiazide. Coadministration of losartan and cimetidine led to an increase of about 18% in AUC of losartan but did not affect the pharmacokinetics of its active metabolite. Co-administration of losartan and phenobarbital led to a reduction of about 20% in the AUC of losartan and that of its active metabolite. A somewhat greater interaction (approximately 40% reduction in the AUC of active metabolite and approximately 30% reduction in the AUC of losartan) has been reported with rifampin. Fluconazole, an inhibitor of cytochrome P450 2C9, decreased the AUC of the active metabolite by approximately 40%, but increased the AUC of losartan by approximately 70% following multiple doses. Conversion of losartan to its active metabolite after intravenous administration is not affected by ketoconazole, an inhibitor of P450 3A4. The AUC of active metabolite following oral losartan was not affected by erythromycin, another inhibitor of P450 3A4, but the AUC of losartan was increased by 30%.
Methods of identifying compounds that inhibit the biological persistence of a Clostridial toxin are disclosed. Methods of identifying compounds that inhibit the enzymatic activity of Clostridial toxin are disclosed. Methods of identifying compounds that inhibit both the biological persistence and enzymatic activity of a Clostridial toxin are disclosed. Methods of identifying compounds that enhance the biological persistence of a Clostridial toxin are disclosed. Methods of identifying compounds that enhance the enzymatic activity of Clostridial toxin are disclosed. Methods of identifying compounds that enhance both the biological persistence and enzymatic activity of a Clostridial toxin are disclosed.
The invention discloses an IL-15/SuIL-15R alpha-mFc-gamma 4 complex protein, which comprises an amino acid sequence shown in SEQ ID No.1 or an amino acid sequence with more than 90% of identity with the SEQ ID No. 1. The invention also discloses a construction method of the IL-15/SuIL-15R alpha-mFc-gamma 4 complex protein. The invention also discloses two expression vectors. The invention also discloses a yeast strain. The invention also discloses application of the IL-15/SuIL-15R alpha-mFc-gamma 4 complex protein in preparing antiviral and antitumor drugs. The invention also discloses application of the expression vector or yeast strain in expression of IL-15/SuIL-15R alpha-mFc-gamma 4 complex protein. The complex protein significantly prolongs the half-life of IL-15.
This invention relates to a tamper resistant medication dispenser. The medication dispenser is programmed to dispense a specified dose of medication at a specified interval. The medication dispenser prevents direct access to the medication by the patient. The medication is dispensed to the patient dissolved in a large volume of liquid to prevent intravenous and intranasal abuse. The medication dispenser can be equipped with a self destruct mechanism when tampered with and have the ability to record video for subsequent monitoring, the actual medication ingestion of the medication infused liquid by the patient. It is especially useful for controlled substances which have high potential for abuse such as opioids, benzodiazepines and barbiturates and anesthetic agents and when patient compliance with medications is necessary such as medications for the treatment of contagious diseases.
Participants randomized to the Cue Reactivity PFI condition will receive personalized feedback at the end of completing 17 days of ecological momentary assessments (EMAs) four times a day. The personalized feedback will be delivered online and contains information summarizing participants' desire to drink as it varied as a function of several real-world factors across the 17-day EMA period.
CYP3A4 Substrates

Sotorasib is a CYP3A4 inducer. Coadministration of LUMAKRAS with a CYP3A4 substrate decreased its plasma concentrations [see Clinical Pharmacology (12.3)], which may reduce the efficacy of the substrate. Avoid coadministration of LUMAKRAS with CYP3A4 sensitive substrates, for which minimal concentration changes may lead to therapeutic failures of the substrate. If coadministration cannot be avoided, increase the sensitive CYP3A4 substrate dosage in accordance with its Prescribing Information.

P-glycoprotein (P-gp) Substrates

Sotorasib is a P-gp inhibitor. Coadministration of LUMAKRAS with a P-gp substrate increased its plasma concentrations [see Clinical Pharmacology (12.3)], which may increase the adverse reactions of the substrate. Avoid coadministration of LUMAKRAS with P-gp substrates, for which minimal concentration changes may lead to serious toxicities. If coadministration cannot be avoided, decrease the P-gp substrate dosage in accordance with its Prescribing Information.

Breast Cancer Resistance Protein (BCRP) Substrates

Sotorasib is a BCRP-inhibitor. Coadministration of LUMAKRAS with a BCRP substrate increased its plasma concentrations [see Clinical Pharmacology (12.3)], which may increase the risk of adverse reactions of the substrate. When coadministered with LUMAKRAS, monitor for adverse reactions of the BCRP substrate and decrease the BCRP substrate dosage in accordance with its Prescribing Information.
The invention relates to medicine for treating internal arteriovenous fistula hardening and a preparing method and device of the medicine. The medicine comprises, by weight, 60-80 parts of potato powder, 10-30 parts of pseudo-ginseng and 10-20 parts of water. The preparing method includes: processing potato powder, adding traditional Chinese medicine and mixing, and measuring water content. The device comprises a vacuum grinding mill. The vacuum grinding mill comprises a sealed cavity communicated with a vacuumizing machine, wherein a cutting shaft with blades is disposed in the sealed cavity, and irregular protrusions are disposed on the inner surface of the sealed cavity. The medicine has the advantages that the medicine can effectively replace mucopolysaccharide polysulfate cream and is harmless and nontoxic to human bodies.